Temisis, a preclinical-stage biotechnology company, is developing innovative therapeutics for patients living with chronic inflammatory and auto-immune diseases, with a primary focus on psoriasis. Temisis’ lead drug candidate, TEM2085, is a first-in-class oral small molecule targeting NFKBIZ signaling, which is a key pro-inflammatory gene involved in the pathogenesis of a variety of immunological indications.

They believe that TEM2085, exhibiting significant efficacy in animal models of immuno-inflammatory diseases and resulting from our drug discovery platform, has the potential to show comparable efficacy to biologics which have demonstrated to date the greatest therapeutic benefit in this area. Temisis’ short-term goal is to move TEM2085 through final stages of preclinical development for clinical evaluation.

Temisis’ lead drug candidate, TEM2085, is a first-in-class oral small molecule targeting NFKBIZ signaling, which is a key pro-inflammatory gene involved in the pathogenesis of a variety of immunological indications. In vitro, TEM2085 shows, at low concentrations, significant inhibition of NFKBIZ expression induced by IL-17/TNFα in keratinocytes. In vivo, TEM2085 has demonstrated in rodent models, at a lower dose, greater therapeutic benefit than the TYK2 inhibitor deucravacitinib against psoriasis and strong protection against ulcerative colitis. By targeting NFKBIZ signaling, TEM2085 and its analogues have the potential to address various immunological disorders.

–  Therapeutic areas: Inflammatory diseases, Auto-immune diseases

–  Based in: Vandœuvre-lès-Nancy (FRANCE)

–  Employees: 1-10

–  Created in: 2017